- Delivering Pan India
Cresp® (Darbepoetin Alfa) Darbepoetin alfa 25, 40, 60, 100 and 200 mcg prefilled syringes by Dr. Reddy’s Laboratories. Genuine stock supplied in bulk/wholesale quantities to hospitals and pharmacies across India by A.K. Pharma, a licensed pharmaceutical distributor in Delhi.
| Composition | Darbepoetin alfa 25, 40, 60, 100, 200 mcg |
|---|---|
| Manufacturer | Dr. Reddy's Laboratories |
| Country | India |
| Pack size | 1 prefilled syringe |
| Storage | Store refrigerated at 2°C to 8°C in the original carton, as stated on the label |
Supplied only against a valid prescription from a registered medical practitioner.
Sourced from authorised channels
Temperature-controlled packing
Hospitals, clinics, pharmacies
Delhi drug licence holder
Cresp® (Darbepoetin Alfa) 25 mcg, 40 mcg, 60 mcg, 100 mcg and 200 mcg Prefilled Syringes: A Sourcing Guide for Hospitals and Pharmacies
Cresp® is a darbepoetin alfa injection (erythropoiesis-stimulating agent) marketed in India by Dr. Reddy’s Laboratories. The decision to prescribe darbepoetin alfa, including patient selection, dose and monitoring, rests entirely with the treating physician. This page provides sourcing and procurement information for hospitals and pharmacies, not clinical or treatment guidance.
As both a trusted medicine distributor in Delhi and a licensed pharmaceutical distributor in Delhi, A.K. Pharma supplies genuine Cresp® (darbepoetin alfa) 25 mcg, 40 mcg, 60 mcg, 100 mcg and 200 mcg prefilled syringes to hospitals and pharmacies across India. Buyers comparing pharmaceutical distribution companies and wholesale pharmaceutical distributors can also browse our full product range and the Blood category. Supply is in bulk/wholesale quantities only.
Cresp contains darbepoetin alfa, supplied as a solution for injection in single-dose prefilled syringes in 25, 40, 60, 100 and 200 mcg strengths. No US label exists for the Cresp brand; the reference prescribing information used below is that of the originator darbepoetin alfa product (Aranesp). Indications and use in India are those printed in the Indian pack insert.
How it works, according to the label: The Aranesp prescribing information (DailyMed) describes darbepoetin alfa as an erythropoiesis-stimulating agent (ESA).
The current US prescribing information for Aranesp (DailyMed) lists the following. Indications in India may differ and are defined by the Indian regulator and the Cresp pack insert.
Published studies of darbepoetin alfa include the TREAT trial (N Engl J Med 2009) in patients with type 2 diabetes, chronic kidney disease and anaemia, and registration studies of darbepoetin alfa in anaemia of chronic kidney disease and chemotherapy-induced anaemia. Results and conclusions are those of the trial authors and the prescribing information; A.K. Pharma does not interpret them.
| Strength | Dosage form | Pack (confirm against the carton) |
|---|---|---|
| Darbepoetin alfa 25 mcg | Solution for injection | Prefilled syringe (confirm against the carton) |
| Darbepoetin alfa 40 mcg | Solution for injection | Prefilled syringe (confirm against the carton) |
| Darbepoetin alfa 60 mcg | Solution for injection | Prefilled syringe (confirm against the carton) |
| Darbepoetin alfa 100 mcg | Solution for injection | Prefilled syringe (confirm against the carton) |
| Darbepoetin alfa 200 mcg | Solution for injection | Prefilled syringe (confirm against the carton) |
Please confirm the current pack and batch with us before ordering. Dose and regimen must be determined and followed exactly as directed by the treating physician and the approved prescribing information.
Hospitals, nephrology and dialysis units, oncology and haematology centres and pharmacies in India that need to source Cresp in bulk quantities from a licensed distributor.
Side effects are listed in the prescribing information and Indian pack insert and are not summarised here. The reference US label for ESAs carries a boxed warning on risks including death, myocardial infarction, stroke, venous thromboembolism and tumour progression; refer to the label and consult the treating physician.
All use should follow the approved prescribing information and the instructions of the treating physician.
Store refrigerated at 2°C to 8°C in the original carton, protected from light, as directed on the pack. Do not freeze or shake.
Cresp is marketed in India by Dr. Reddy’s Laboratories. A.K. Pharma is a licensed distributor and does not manufacture the product. As one of the pharmaceutical distributors serving Indian hospitals, we source Cresp through authorised channels and supply it with pack and batch details. Buyers comparing a pharmaceutical wholesale distributors list or a pharma distribution company can verify our credentials on the About Us page.
Is Cresp available in India?
A.K. Pharma supplies Cresp® (darbepoetin alfa) 25 mcg, 40 mcg, 60 mcg, 100 mcg and 200 mcg prefilled syringes to hospitals and pharmacies in India. Contact us for current availability.
What does Cresp contain?
Cresp contains darbepoetin alfa, marketed by Dr. Reddy’s Laboratories. The details of use are those on its label.
Can I order a single pack?
A.K. Pharma is a distributor and supplies bulk/wholesale quantities only, not one or two pieces.
How should Cresp be stored?
The label directs refrigerated storage at 2°C to 8°C. Check the carton for the exact instructions.
Which Cresp strengths does A.K. Pharma supply?
Contact us for current availability of the 25, 40, 60, 100 and 200 mcg syringes.
Does A.K. Pharma advise on dosing or suitability?
No. Treatment decisions, including dosing, rest solely with the treating physician and the approved prescribing information.
How do I request a quote?
Call or WhatsApp us, or use the contact details below.
📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052
📞 011 4172 6999
📱 WhatsApp: +91 9810034827
🌐 akpharma.in
Disclaimer: This page is intended for informational and sourcing/procurement purposes only and does not constitute medical or clinical advice. A.K. Pharma is a licensed medicine distributor, not a healthcare provider, and does not provide clinical guidance. All treatment decisions, including drug selection and dosing, rest solely with the treating physician and should follow the approved prescribing information.
